Pay in 4 interest-free payments of $6.36 Learn more
Ships within 48 hours · Estimated delivery Nov 7 - Nov 12
Drifting the injection day forward and backward compresses some intervals and stretches others, which introduces variability the dosing regimen was designed to avoid
doi: 10.1136/bmj.c869 Summary Keywords obesity, GLP-1, GLP-1 receptor analog, exenatide, pediatrics, glycemic control, GLP-1 receptor agonist, treatment Citation Stenlid R, Cerenius SY, Wen Q, Aydin BK, Manell H, Chowdhury A, Kristinsson H, Ciba I, Gjessing ES, Mrwald K, Gomahr J, Heu V, Weghuber D, Forslund A and Bergsten P (2023) Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control
J., Dreher, F
Chan School of PublicHealth)
Protein S-nitrosylation: a chemical modification with ubiquitous biological activities
US$ 27.98
US$ 24.49
US$ 21.75
US$ 21.22
